The Impact of Lipoprotein(a) Determination in Cardiovascular Risk Stratification Among People Living with HIV
Authors:
- Carmen Ramos Alejos-PitaCACarmen Ramos Alejos-Pita
- Diego José Rodríguez TorresDTDiego José Rodríguez Torres
- Tatiana Mata ForteTFTatiana Mata Forte
- Judith del Carmen López GaliendoJGJudith del Carmen López Galiendo
- Beatriz Tendero de la AsunciónBABeatriz Tendero de la Asunción
- Joaquín Enrique Gómez SanzJSJoaquín Enrique Gómez Sanz
- Juan José Reyes LujánJLJuan José Reyes Luján
- Matteo RomanoMRMatteo Romano
- Salvador Álvarez AntónSASalvador Álvarez Antón
- Edurne López SoberónESEdurne López Soberón
- Francisco Javier Membrillo de NovalesFNFrancisco Javier Membrillo de Novales
- Miriam Estébanez MuñozMMMiriam Estébanez Muñoz
Preprint
- 13 November 2025
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Introduction: Human immunodeficiency virus (HIV) infection has become a chronic condition due to antiretroviral therapy (ART), which has increased life expectancy but is also associated with a higher burden of cardiovascular disease (CVD) in people living with HIV (PLHIV). Lipoprotein(a) [Lp(a)] is an independent cardiovascular risk biomarker; however, its role in PLHIV remains unclear. This study evaluated the relationship between Lp(a) and cardiovascular risk and explored its association with subclinical coronary artery disease. Materials and Methods: Cross-sectional study included PLHIV aged ≥40 years on stable ART with sustained viral suppression. Individuals with prior cardiovascular events or type 1/advanced type 2 diabetes were excluded. Lp(a) levels and clinical data were collected. Cardiovascular risk was estimated using validated clinical scores; participants with ≥10% risk underwent coronary computed tomography angiography (CTA) to assess coronary anatomy. Results: A total of 69 patients were included (81% male; mean age 54 years). The mean Lp(a) level was 66.7 nmol/L; 29% had ≥75 nmol/L and 23% ≥125 nmol/L. A non-significant inverse correlation was observed between Lp(a) levels and ART duration (r = –0.209; p = 0.08). Among those with elevated Lp(a), a higher proportion had vulnerable plaques on CTA, although this was not statistically significant. Conclusions: In this cohort of virologically suppressed PLHIV, an inverse trend was observed between ART duration and Lp(a) levels. In the subgroup of moderate-to-high cardiovascular risk, the prevalence of coronary plaque vulnerability features was higher among those with elevated Lp(a), highlighting a possible link between Lp(a) and subclinical atherosclerosis in this population.Keywords
All Related Versions
This publication has 18 references indexed in Scilit:
- Association Between Lipoprotein(a) and Obstructive Coronary Artery Disease and High-Risk Plaque: Insights From the PROMISE TrialThe American Journal of Cardiology, 2024
- Association of Lipoprotein(a) with peri-coronary inflammation in persons with and without HIV infectionJournal of Clinical Lipidology, 2024
- Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a)JAMA, 2023
- Lipoprotein(a) and its Significance in Cardiovascular DiseaseJAMA Cardiology, 2022
- Lipoprotein(a): An underestimated inflammatory mastermindAtherosclerosis, 2022
- 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in AdultsCanadian Journal of Cardiology, 2021
- Coronary Atherosclerotic Precursors of Acute Coronary SyndromesJACC, 2018
- High prevalence at computed coronary tomography of non-calcified plaques in asymptomatic HIV patients treated with HAART: A meta-analysisAtherosclerosis, 2015
- Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaborationThe Lancet, 2014
- LDL subclasses and lipoprotein-phospholipase A2 activity in suppressed HIV-infected patients switching to raltegravir: Spiral substudyAtherosclerosis, 2012